

Technology Appraisal Committee Meeting (Committee [A])

Minutes: **Confirmed**

Date and Time: 15th February 2016

Venue: **Prospero House**
265 Borough High Street
SW1A 2BU

Present:	1. Dr Jane Adam 2. Professor Iain Squire Chair 3. Ms Ellen Rule 4. Dr John Watkins 5. Mrs Pamela Rees 6. Professor Olivia Wu 7. Dr Nerys Woolacott 8. Dr Brian Shine 9. Mr David Thomson 10. Dr Justin Daniels 11. Dr Andrew England 12. Dr Graham Ash 13. Mr Stephen Sharp	Vice-	Present for all notes Present for all notes
-----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In attendance:

Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Bijal Joshi	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Administrator, National Institute for Health and Care Excellence	Present for all notes
Christian Griffiths	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1-16
Eleanor Donegan	Technical Adviser,	Present for notes 1-16

ERG – Liverpool
implementation and
review group

Nigel Fleeman	Research Fellow	Present for notes 1-16
Adrian Bagust	Professor of Modelling in Health	Present for notes 1-16
Ewen Cummings	Health Economist	Present for notes 17- 29
Norman Waugh	Professor of Public Health	Present for notes 17-29
Professor Christian Ottensmeier	Clinical expert, Professor of Experimental Cancer medicine, and Consultant Medical Oncologist, nominated by NCRI/RCP/RCR/ACP	Present for all notes 1-16
Professor Harrington	Kevin Clinical expert, Professor of biological cancer therapies nominated by Amgen and Melanoma UK	Present for all notes 1-16
Mrs Gillian Nuttall	Patient expert, nominated by Melanoma Uk	Present for notes 1-16
Mrs Jackie Hodgetts	Patient expert, British Association of Skin Cancer Specialist Nurses	Present for notes 1-16

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Talimogene laherparepvec for treating metastatic melanoma [ID508].
2. The Chair informed the Committee of the non-public observers at this meeting: Joshua South and Chloe Kastoryano
3. Apologies were received from Dr Jeremy Braybrooke, Dr Gerardine Bryant, Professor Aileen Clarke, Mrs Sarah Parry, Mr Adrian Griffin, Dr Rachel Hobson Dr Anne McCune, Professor John McMurray, Dr Mohit Misra and Dr Paul Robinson

Notes from the last meeting

4. Minutes from the last meeting were agreed.

Appraisal of Talimogene laherparepvec for treating metastatic melanoma [ID508].

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Christian Ottensmeier Professor Kevin Harrington and Mrs Jackie Hodgetts to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Amgen to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Jane Adam, Ms Ellen Rule, Dr John Watkins, Mrs Pamela Rees, Professor Olivia Wu, Dr Nerys Woolacott, Dr Brian Shine, Mr David Thomson, Dr Justin Daniels, Dr Andrew England, Dr Graham Ash and Mr Stephen Sharp all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Talimogene laherparepvec for treating metastatic melanoma
 - 7.2. Subsequent, to the meeting Professor Iain Squired declared a non-personal specific financial interest as he has participated in clinical studies sponsored by Amgen. These trials were in cardiovascular conditions. Professor Iain Squire also declared a personal pecuniary interest as he has accepted fees for participation in education events

from Novartis. These events concerned cardiovascular disease. Both of these declarations were not made at the meeting.

9.2.1 It was agreed that these declarations would not prevent Professor Iain Squire from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Talimogene laherparepvec for treating metastatic melanoma.

9. The Chair asked all other invited guests ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Adrian Bagust, Nigel Fleeman and Mrs Gillian Nuttall, declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Talimogene laherparepvec for treating metastatic melanoma.

9.2. Professor Kevin Harrington declared a personal non-specific financial interest as has received research funding and honoraria from Amgen.

9.2.1. It was agreed that this declaration would not prevent Professor Kevin Harrington from participating in this section of the meeting

9.3. Professor Christian Ottensmeier declared a non - personal non-specific financial interest as he was involved in a collaborative phase I study funded by CRU for AMS319 Amgen compound, cofounded by Amgen and he is the chief investigator

9.2.2. It was agreed that this declaration would not prevent Professor Christian Ottensmeier from participating in this section of the meeting

9.3. Mrs Jackie Hodgetts declared a personal, non-specific financial interest as she has received honoraria from Amgen for attending advisory boards. She advised on developing patient information and teaching material for health care professionals.

9.3.1. It was agreed that this declaration would not prevent Mrs Jackie Hodgetts from participating in this section of the meeting

10. The Chair introduced the lead team, Dr John Watkins, Ms Pamela Rees and Ms Ellen Rule who gave presentations on the clinical effectiveness and cost effectiveness Talimogene laherparepvec for treating metastatic melanoma

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of Talimogene laherparepvec for treating metastatic melanoma.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document in line with their decisions.

Appraisal of Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756]

Part 1 – Open session

17. The Chair welcomed the invited experts: Nigel Fleeman and Adrian Bagust to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from AstraZeneca, Boehringer Ingelheim and Janssen to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
 - 19.1. Dr Jane Adam, Ms Ellen Rule, Dr John Watkins, Mrs Pamela Rees, Professor Olivia Wu, Dr Nerys Woolacott, Dr Brian Shine, Mr David Thomson, Dr Justin Daniels, Dr Andrew England, Dr Graham Ash and Mr Stephen Sharp all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756]**
 - 19.2. Mr Adrian Griffin was absent as he declared a personal specific financial interest, as Janssen are part of the company he works for (JnJ).
 - 19.3. Professor Aileen Clarke was absent, as she is a member of the Assessment Group, Warwick Evidence.
 - 19.4. Dr Rachel Hobson was absent as she declared a personal specific financial interest. She was on an advisory board for Astra-Zeneca during

December 2014 and she was also on two advisory boards for Janssen which were specifically about canagliflozin within the last 12 months.

- 19.5. Dr Paul Robinson was absent as he declared a personal specific financial interest, His employer, Merck Sharpe and Dohme, is the manufacturer of the comparator, sitagliptin.
20. The Chair asked all NICE Staff to declare any relevant interests.
 - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756].
21. The Chair asked all other invited guests, not including observers) to declare their relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756].
22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued . This information was supplied by the Company.
27. The Committee continued to discuss the clinical and cost effectiveness Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes [ID756].

28. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

29. Tuesday 15th March 2015, at the **National Institute for Health and Care Excellence, 10 Spring Garden, SW1A 2BU**